June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Transplantation of human retinal progenitor cells into the P23H rat improves the scotopic ERG.
Author Affiliations & Notes
  • Ma'ayan Semo
    UCL Institute of Ophthalmology, London, United Kingdom
  • Aisling Lynch
    UCL Institute of Ophthalmology, London, United Kingdom
  • Nasrin Haamedi
    UCL Institute of Ophthalmology, London, United Kingdom
  • David Carter
    UCL Institute of Ophthalmology, London, United Kingdom
  • John Sinden
    ReNeuron, Guildford, United Kingdom
  • Michael Young
    Massachusetts Eye and Ear, Schepens Eye Research Institute, Boston, MA
  • Lara Stevanato
    ReNeuron, Guildford, United Kingdom
  • Sara Patel
    ReNeuron, Guildford, United Kingdom
  • Anthony Vugler
    UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships Ma'ayan Semo, ReNeuron (F); Aisling Lynch, None; Nasrin Haamedi, ReNeuron (F); David Carter, None; John Sinden, ReNeuron (E); Michael Young, ReNeuron (C); Lara Stevanato, ReNeuron (E); Sara Patel, ReNeuron (E); Anthony Vugler, ReNeuron (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1821. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ma'ayan Semo, Aisling Lynch, Nasrin Haamedi, David Carter, John Sinden, Michael Young, Lara Stevanato, Sara Patel, Anthony Vugler; Transplantation of human retinal progenitor cells into the P23H rat improves the scotopic ERG.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1821.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The P23H rat is a model of human autosomal dominant retinitis pigmentosa. Here we investigate the potential of a clinical grade human retinal progenitor cell (hRPC) line to improve or preserve vision in this model following an established tolerization protocol.

Methods: The hRPC line used in this study (GS089) was derived from human fetal retina, obtained in compliance with the procedures of The European Union Tissues and Cells Directive (EUCTD), The UK Human Tissue Act and USA 21 Code of Federal Regulations Part 1271. The hRPCs were manufactured under GMP conditions and banked at passage 8. Cryopreserved cells were then cultured and formulated as drug product, passage 9.<br /> On the day of birth (postnatal day 0 (P0)), heterozygote P23H rat pups received a single intra peritoneal injection of hRPCs (5X104 in 1μl). From P21 onwards the rats were administered 210mg/L oral cyclosporine. At P24-25 the left eye received an intravitreal injection of hRPCs (5X104 in 2μl, n=8) or vehicle (HBSS-NAC, n=8). At P53-57 simultaneous bilateral electroretinogram (ERG) recordings of scotopic and photopic visual function was performed, using the Diagnosys system and Espion software. At P61-63, rats were perfused and their eyes were processed for immunofluorescence.

Results: The raw scotopic and photopic ERG data did not reveal any significant effect of transplantation. However, as simultaneous bilateral ERGs were recorded, within animal (left eye - right eye) corrections were made. This revealed a subtle but significant improvement in the scotopic a- (by -6 µV) and b-wave (by 34 µV) amplitudes at the highest light intensity tested (28 cd/s/m2). The vehicle treatment consistently reduced b-wave amplitude significantly (by -19 µV) at the lowest light intensity tested (0.3x10-3 cd/s/m2). At P61-63 very few surviving hRPCs were detected in the transplanted eyes, however auto-fluorescent macrophage activity was clearly present.

Conclusions: The intravitreal transplantion of hRPCs improved the scotopic ERG in the P23H rat. The mechanism for this may be linked to neuroprotective factors released by the hRPCs prior to rejection and/or the protective effects of the host inflammatory/immune response to the xenograft. Importantly, the tolerization protocol employed here was ineffective in preventing rejection of hRPCs.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.